Journal of Obesity & Metabolic Syndrome最新文献

筛选
英文 中文
Ratio of Skeletal Muscle Mass to Visceral Fat Area Is a Useful Marker for Assessing Left Ventricular Diastolic Dysfunction among Koreans with Preserved Ejection Fraction: An Analysis of the Random Forest Model. 骨骼肌质量与内脏脂肪面积之比是评估韩国人左心室舒张功能障碍的有用标记:随机森林模型的分析。
IF 4.7
Journal of Obesity & Metabolic Syndrome Pub Date : 2025-01-30 Epub Date: 2025-01-14 DOI: 10.7570/jomes24027
Jin Kyung Oh, Yuri Seo, Wonmook Hwang, Sami Lee, Yong-Hoon Yoon, Kyupil Kim, Hyun Woong Park, Jae-Hyung Roh, Jae-Hwan Lee, Minsu Kim
{"title":"Ratio of Skeletal Muscle Mass to Visceral Fat Area Is a Useful Marker for Assessing Left Ventricular Diastolic Dysfunction among Koreans with Preserved Ejection Fraction: An Analysis of the Random Forest Model.","authors":"Jin Kyung Oh, Yuri Seo, Wonmook Hwang, Sami Lee, Yong-Hoon Yoon, Kyupil Kim, Hyun Woong Park, Jae-Hyung Roh, Jae-Hwan Lee, Minsu Kim","doi":"10.7570/jomes24027","DOIUrl":"10.7570/jomes24027","url":null,"abstract":"<p><strong>Background: </strong>Although the presence of both obesity and reduced muscle mass presents a dual metabolic burden and additively has a negative effect on a variety of cardiometabolic parameters, data regarding the associations between their combined effects and left ventricular diastolic function are limited. This study investigated the association between the ratio of skeletal muscle mass to visceral fat area (SVR) and left ventricular diastolic dysfunction (LVDD) in patients with preserved ejection fraction using random forest machine learning.</p><p><strong>Methods: </strong>In total, 1,070 participants with preserved left ventricular ejection fraction who underwent comprehensive health examinations, including transthoracic echocardiography and bioimpedance body composition analysis, were enrolled. SVR was calculated as an index of sarcopenic obesity by dividing the appendicular skeletal muscle mass by the visceral fat area.</p><p><strong>Results: </strong>In the random forest model, age and SVR were the most powerful predictors of LVDD. Multivariate logistic regression analysis demonstrated that older age (adjusted odds ratio [OR], 1.11; 95% confidence interval [CI], 1.07 to 1.15) and lower SVR (adjusted OR, 0.08; 95% CI, 0.01 to 0.57) were independent risk factors for LVDD. SVR showed a significant improvement in predictive performance and fair predictability for LVDD, with the highest area under the curve noted in both men and women, with statistical significance. In non-obese and metabolically healthy individuals, the lowest SVR tertile was associated with a greater risk of LVDD compared to the highest SVR tertile.</p><p><strong>Conclusion: </strong>Decreased muscle mass and increased visceral fat were significantly associated with LVDD compared to obesity, body fat composition, and body muscle composition indices.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":" ","pages":"54-64"},"PeriodicalIF":4.7,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11799598/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of Obesity Treatments on Bone Health: Insights from Recent Research. 肥胖治疗对骨骼健康的影响:来自最近研究的见解。
IF 4.7
Journal of Obesity & Metabolic Syndrome Pub Date : 2025-01-30 Epub Date: 2025-01-16 DOI: 10.7570/jomes25001
Ji Hye Heo
{"title":"The Impact of Obesity Treatments on Bone Health: Insights from Recent Research.","authors":"Ji Hye Heo","doi":"10.7570/jomes25001","DOIUrl":"10.7570/jomes25001","url":null,"abstract":"","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":" ","pages":"1-3"},"PeriodicalIF":4.7,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11799602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Anti-Obesity Strategies on Bone Mineral Density: A Comprehensive Meta-Analysis of Randomized Controlled Trials. 抗肥胖策略对骨密度的影响:一项随机对照试验的综合meta分析。
IF 4.7
Journal of Obesity & Metabolic Syndrome Pub Date : 2025-01-30 Epub Date: 2025-01-13 DOI: 10.7570/jomes24009
Myung Jin Kim, Seonok Kim, Han Na Jung, Chang Hee Jung, Woo Je Lee, Yun Kyung Cho
{"title":"Effects of Anti-Obesity Strategies on Bone Mineral Density: A Comprehensive Meta-Analysis of Randomized Controlled Trials.","authors":"Myung Jin Kim, Seonok Kim, Han Na Jung, Chang Hee Jung, Woo Je Lee, Yun Kyung Cho","doi":"10.7570/jomes24009","DOIUrl":"10.7570/jomes24009","url":null,"abstract":"<p><strong>Background: </strong>Although an appropriate weight management strategy is essential for obese individuals, weight loss can have adverse effects on bone mineral density (BMD). We conducted a systematic review of randomized controlled trials to evaluate changes in BMD after the implementation of various weight loss strategies.</p><p><strong>Methods: </strong>The PubMed, Embase, Web of Science, and Cochrane Library databases were searched to find articles published from database inception until June 2023. Randomized controlled trials of various treatments for obese patients that reported changes in BMD were selected. The primary outcome was BMD of the whole body, lumbar spine, and total hip, measured using dual X-ray absorptiometry.</p><p><strong>Results: </strong>Eighteen randomized controlled trials involving 2,510 participants with obesity were included in the analysis. At follow-up examination, the BMD of the lumbar spine decreased significantly after metabolic surgery (mean difference [MD]=-0.40 g/cm<sup>2</sup>; 95% confidence interval [CI], -0.73 to -0.07; I<sup>2</sup>=0%); lifestyle and pharmacological interventions did not result in a significant decrease in BMD at any location. Metabolic surgery also produced the most substantial difference in weight, with an MD of -3.14 (95% CI, -3.82 to -2.47).</p><p><strong>Conclusion: </strong>This meta-analysis is the first to examine the effects of all categories of anti-obesity strategies, including the use of anti-obesity medications, on BMD. Bariatric metabolic surgery can have adverse effects on BMD. Moreover, medications can be used as a treatment for weight loss without compromising bone quality.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":" ","pages":"41-53"},"PeriodicalIF":4.7,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11799600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding Adipose Tissue Dysfunction. 了解脂肪组织功能障碍。
IF 4.7
Journal of Obesity & Metabolic Syndrome Pub Date : 2024-12-30 DOI: 10.7570/jomes24013
Matthias Blüher
{"title":"Understanding Adipose Tissue Dysfunction.","authors":"Matthias Blüher","doi":"10.7570/jomes24013","DOIUrl":"10.7570/jomes24013","url":null,"abstract":"<p><p>Diseases affecting adipose tissue (AT) function include obesity, lipodystrophy, and lipedema, among others. Both a lack of and excess AT are associated with increased risk for developing diseases including type 2 diabetes mellitus, hypertension, obstructive sleep apnea, and some types of cancer. However, individual risk of developing cardiometabolic and other 'obesity-related' diseases is not entirely determined by fat mass. Rather than excess fat accumulation, AT dysfunction may represent the mechanistic link between obesity and comorbid diseases. There are people who remain metabolically healthy despite obesity, whereas people with normal weight or very low subcutaneous AT mass may develop typically obesity-related diseases. AT dysfunction is characterized by adipocyte hypertrophy, impaired subcutaneous AT expandability (ectopic fat deposition), hypoxia, a variety of stress, inflammatory processes, and the release of proinflammatory, diabetogenic, and atherogenic signals. Genetic and environmental factors might contribute to AT heterogeneity either alone or via interaction with intrinsic biological factors. However, many questions remain regarding the mechanisms of AT dysfunction initiation and whether and how it could be reversed. Do AT signatures define clinically relevant subtypes of obesity? Is the cellular composition of AT associated with variation in obesity phenotypes? What roles do environmental compounds play in the manifestation of AT dysfunction? Answers to these and other questions may explain AT disease mechanisms and help to define strategies for improving AT health. This review focuses on recent advances in our understanding of AT biology.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"33 4","pages":"275-288"},"PeriodicalIF":4.7,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Growth Hormone, Hypothalamic Inflammation, and Aging. 生长激素,下丘脑炎症和衰老。
IF 4.7
Journal of Obesity & Metabolic Syndrome Pub Date : 2024-12-30 Epub Date: 2024-12-06 DOI: 10.7570/jomes24032
Licio A Velloso, Jose Donato
{"title":"Growth Hormone, Hypothalamic Inflammation, and Aging.","authors":"Licio A Velloso, Jose Donato","doi":"10.7570/jomes24032","DOIUrl":"10.7570/jomes24032","url":null,"abstract":"<p><p>While inflammation is a crucial response in injury repair and tissue regeneration, chronic inflammation is a prevalent feature in various chronic, non-communicable diseases such as obesity, diabetes, and cancer and in cardiovascular and neurodegenerative diseases. Long-term inflammation considerably affects disease prevalence, quality of life, and longevity. Our research indicates that the growth hormone/insulin-like growth factor 1 (GH/IGF-1) axis is a pivotal regulator of inflammation in some tissues, including the hypothalamus, which is a key player in systemic metabolism regulation. Moreover, the GH/IGF-1 axis is strongly linked to longevity, as GH- or GH receptor-deficient mice live approximately twice as long as wild-type animals and exhibit protection against aging-induced inflammation. Conversely, GH excess leads to increased neuroinflammation and reduced longevity. Our review studies the associations between the GH/IGF-1 axis, inflammation, and aging, with a particular focus on evidence suggesting that GH receptor signaling directly induces hypothalamic inflammation. This finding underscores the significant impact of changes in the GH axis on metabolism and on the predisposition to chronic, non-communicable diseases.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":" ","pages":"302-313"},"PeriodicalIF":4.7,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142786036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Obesity and Polycystic Ovary Syndrome. 肥胖症与多囊卵巢综合症。
IF 4.7
Journal of Obesity & Metabolic Syndrome Pub Date : 2024-12-30 Epub Date: 2024-12-20 DOI: 10.7570/jomes24035
Jin Ju Kim
{"title":"Obesity and Polycystic Ovary Syndrome.","authors":"Jin Ju Kim","doi":"10.7570/jomes24035","DOIUrl":"10.7570/jomes24035","url":null,"abstract":"<p><p>The core pathophysiology of polycystic ovary syndrome involves an overproduction of androgens primarily originating from ovarian thecal cells. Two major external triggers promote androgen overproduction in the ovaries: the increased secretion of luteinizing hormone, a consequence of aberrant hypothalamic gonadotropin-releasing hormone secretion dynamics, and compensatory hyperinsulinemia resulting from insulin resistance. Obesity interacts with polycystic ovary syndrome in multiple ways, but a major role of obesity in its pathophysiology is the exacerbation of insulin resistance. Additionally, obesity contributes to polycystic ovary syndrome by facilitating the conversion of precursor hormones to testosterone within adipose cells. Moreover, obesity can lead to relative hyperandrogenemia, which is marked by lower levels of sex hormone binding globulin and increased availability of free testosterone to target tissues. Also, obesity affects the secretion of gonadotropins, resulting in heightened luteinizing hormone secretion or increased sensitivity of thecal cells to luteinizing hormone. Obesity-related insulin resistance might be amplified by alterations in adipokine and inflammatory cytokine production. Ultimately, obesity and polycystic ovary syndrome might share a common genetic predisposition. The cornerstone of managing polycystic ovary syndrome is to address individual symptoms such as hyperandrogenism (hirsutism, acne, and female type boldness), menstrual irregularities, and infertility stemming from anovulation. However, obesity is integral to the pathophysiology of polycystic ovary syndrome and exacerbates all of its features. Therefore, lifestyle modifications aimed at weight reduction should be the primary strategy in overweight or obese women with polycystic ovary syndrome.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":" ","pages":"289-301"},"PeriodicalIF":4.7,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 替西肽对血脂的影响:随机对照试验的系统评价和荟萃分析。
IF 4.7
Journal of Obesity & Metabolic Syndrome Pub Date : 2024-12-30 Epub Date: 2024-12-17 DOI: 10.7570/jomes24008
Muhammad Umar Mahar, Omar Mahmud, Salaar Ahmed, Saleha Ahmed Qureshi, Wasila Gul Kakar, Syeda Sadia Fatima
{"title":"The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","authors":"Muhammad Umar Mahar, Omar Mahmud, Salaar Ahmed, Saleha Ahmed Qureshi, Wasila Gul Kakar, Syeda Sadia Fatima","doi":"10.7570/jomes24008","DOIUrl":"10.7570/jomes24008","url":null,"abstract":"<p><strong>Background: </strong>Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP)-glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of various metabolic disorders. We performed a meta-analysis of randomized data on the effects of tirzepatide on serum lipid levels.</p><p><strong>Methods: </strong>We systematically searched the PubMed and ClinicalTrials.gov databases for relevant data from randomized controlled clinical trials. All articles were screened, reviewed, and extracted by at least two independent authors, with conflicts resolved by consensus. Four hundred and thirty-three records were identified in the initial literature search; 18 of them were identified for full-text review, and 14 of those were systematically reviewed and included in the analysis. The meta-analysis was performed using an inverse variance random-effects model.</p><p><strong>Results: </strong>Fourteen articles that reported data from 13 randomized controlled clinical trials were included in the review. Nine trials had a low risk of bias, two had a moderate risk, and two had a high risk of bias. The pooled analysis showed that tirzepatide was efficacious at improving all lipid markers, including cholesterol and triglycerides. Moreover, a clear dose response trend was visible across results from groups taking 5, 10, and 15 mg of tirzepatide.</p><p><strong>Conclusion: </strong>There is growing evidence to support the use of tirzepatide in patients with metabolic diseases such as type 2 diabetes mellitus, metabolic syndrome, and obesity. Our results demonstrate that tirzepatide significantly improves all aspects of patient metabolism and might be superior in this regard to conventional agents such as insulin formulations or traditional GLP-1 agonists.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":" ","pages":"348-359"},"PeriodicalIF":4.7,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Weightism in Asia: A Narrative Review and Implications for Practice. 亚洲的体重主义:叙事回顾与实践启示》。
IF 4.7
Journal of Obesity & Metabolic Syndrome Pub Date : 2024-12-30 Epub Date: 2024-12-18 DOI: 10.7570/jomes24033
Shubashini Mathialagan, Poh Li Lau
{"title":"Weightism in Asia: A Narrative Review and Implications for Practice.","authors":"Shubashini Mathialagan, Poh Li Lau","doi":"10.7570/jomes24033","DOIUrl":"10.7570/jomes24033","url":null,"abstract":"<p><p>Weightism, also known as weight-related discrimination, is pervasive and believed to be one of the socially accepted types of discrimination in Asia. Weightism is pervasive, impactful, and has significant repercussions on individuals grappling with excess weight. Despite being a major risk factor for obesity, excess weight is not well documented in the Asian literature. This narrative review explores compelling evidence indicating that weightism adversely affects both physical and psychological well-being across various aspects of life. Research findings suggest that weightism be deemed socially unacceptable in Asia to mitigate the obesity epidemic and enhance overall well-being. Consequently, several recommendations for reducing weight stigma in Asian culture are proposed to support a healthier future.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":" ","pages":"314-325"},"PeriodicalIF":4.7,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anthropometric Changes in Female Participants Enrolled in a Combined Aerobic and Resistance Training Program for Longer than 1 Year: A Cohort Study. 参加有氧和抗阻联合训练计划超过1年的女性参与者的人体测量变化:一项队列研究。
IF 4.7
Journal of Obesity & Metabolic Syndrome Pub Date : 2024-12-30 Epub Date: 2024-10-30 DOI: 10.7570/jomes23061
Jung-Sun Lim, Hee-Jin Hwang, Yoon Hee Eum, Ho Jun Kim, Booyoon Cheung, Han Jin Oh, Bumjo Oh
{"title":"Anthropometric Changes in Female Participants Enrolled in a Combined Aerobic and Resistance Training Program for Longer than 1 Year: A Cohort Study.","authors":"Jung-Sun Lim, Hee-Jin Hwang, Yoon Hee Eum, Ho Jun Kim, Booyoon Cheung, Han Jin Oh, Bumjo Oh","doi":"10.7570/jomes23061","DOIUrl":"10.7570/jomes23061","url":null,"abstract":"<p><strong>Background: </strong>To analyze the anthropometric changes in women who had participated in a combined resistance and aerobic training program for more than a year and to determine the effect of the exercise on weight loss.</p><p><strong>Methods: </strong>A total of 9,128 women aged between 20 and 60 years who registered in the Curves program, which employs a combination of resistance and aerobic training exercises, and who participated for more than 1 year were included in our analysis. The women were divided into groups according to exercise frequency: <1, 1, 2, and ≥3 days/week. Weight and waist circumference were measured at the beginning and end of the follow-up period.</p><p><strong>Results: </strong>The average follow-up duration was 625.3±151.2 days. Waist circumference and body weight decreased more on average in those who participated more frequently in exercise. The achievement of more than 5% weight reduction became more likely with increasing frequency of exercise participation. The odds ratios of more than 5% weight reduction between the exercise groups were 1.47, 1.58, and 2.05 for the 1, 2, and ≥3 days/week exercise groups, respectively.</p><p><strong>Conclusion: </strong>Women who participated in a combined resistance and aerobic training program for more than a year lost weight in a dose-dependent manner.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"33 4","pages":"367-373"},"PeriodicalIF":4.7,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704220/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationships of Thickness of Perirenal Fat with Urinary Levels of MCP-1 and NGAL in Patients with Hypertension. 高血压患者肾周脂肪厚度与尿液中 MCP-1 和 NGAL 水平的关系
IF 4.7
Journal of Obesity & Metabolic Syndrome Pub Date : 2024-12-30 Epub Date: 2024-09-13 DOI: 10.7570/jomes24002
Anna Bragina, Yulia Rodionova, Konstantin Osadchiy, Daria Bayutina, Maria K Vasilchenko, Alexander Fomin, Valeriy Podzolkov
{"title":"Relationships of Thickness of Perirenal Fat with Urinary Levels of MCP-1 and NGAL in Patients with Hypertension.","authors":"Anna Bragina, Yulia Rodionova, Konstantin Osadchiy, Daria Bayutina, Maria K Vasilchenko, Alexander Fomin, Valeriy Podzolkov","doi":"10.7570/jomes24002","DOIUrl":"10.7570/jomes24002","url":null,"abstract":"<p><strong>Background: </strong>We conducted a study to determine the relationships between perirenal fat (PRF) thickness and urinary levels of monocyte chemoattractant protein-1 (MCP-1) and neutrophil gelatinase-associated lipocalin (NGAL) in patients with hypertension (HTN).</p><p><strong>Methods: </strong>In 338 HTN patients (aged 63.5±12.3 years on average), MCP-1 and NGAL levels were studied using enzyme-linked immunosorbent assay (ELISA). To measure PRF thickness, all patients underwent CT scans.</p><p><strong>Results: </strong>We considered PRF thickness ≥1.91 cm as the diagnostic threshold for perirenal obesity. Patients with excessive PRF thickness exhibited significantly lower levels of MCP-1 and NGAL compared with those with PRF thickness ≥1.91 cm: 0.98 pg/mL (interquartile range [IQR], 0.21 to 2.05) vs. 2.35 pg/mL (IQR, 0.37 to 5.22) for MCP-1 and 50.0 pg/mL (IQR, 48.9 to 67.8) vs. 98.3 pg/mL (IQR, 68.4 to 187.1) for NGAL. We found a relationship of PRF thickness with both MCP-1 (r=0.46, <i>P</i><0.05) and NGAL (r=0.53, <i>P</i><0.05), the levels of which were significantly different in patients with first- and third-stage chronic kidney disease: 0.33 pg/mL (IQR, 0.21 to 1.35) vs. 4.47 pg/mL (IQR, 0.23 to 10.81); 50.0 pg/mL (IQR, 49.4 to 85.5) vs. 126.45 pg/mL (IQR, 57.5 to 205.15), respectively (<i>P</i>=0.04). Patients with metabolically healthy obesity (MHO) had significantly lower MCP-1 levels than those with metabolically unhealthy obesity (MUO): 0.65 pg/mL (IQR, 0.21 to 2.15) vs. 3.28 pg/mL (IQR, 2.05 to 5.22) (<i>P</i>=0.014). MHO patients showed significantly lower NGAL levels than MUO patients: 50.0 pg/mL (IQR, 49.4 to 62.2) vs. 98.3 pg/mL (IQR, 50.0 to 174.8) (<i>P</i>=0.04). Multiple linear regression analysis revealed significant relationships of MCP-1 with PRF thickness (β±standard error, 0.41±0.15; <i>P</i><0.001) and smoking (0.26±0.13; <i>P</i>=0.01) and of NGAL with age (0.45±0.16; <i>P</i><0.01) and PRF thickness (0.49±0.15; <i>P</i><0.001).</p><p><strong>Conclusion: </strong>We identified higher concentrations of renal fibrosis markers in patients with perirenal and MUO as well as a link between PRF thickness and MCP-1 and NGAL levels in urine.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":" ","pages":"360-366"},"PeriodicalIF":4.7,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信